Nevertheless, therapeutic targets including Fibroblast Growth Factor 19 (FGF19), have been successfully validated in pre-clinical settings after they were identified from bioinformatic analysis (52), which motivates us to continue bioinformatic analysis of some refractory tumors, including ACC. The gene discussed is FGF19; the disease is adrenal cortex carcinoma.